At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth ...
Evaxion's AI-Immunology platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combinin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback